Sarasota Memorial Hospital is part of a global research effort on an option to traditional cardiac resynchronization therapy.
Shanghai, China - The first patient implants of the Boston Scientific Corporation COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang ...
Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...
Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...
Patients who need cardiac resynchronization therapy may be eligible for Cedars-Sinai clinical trials
LOS ANGELES (March 8, 2002) – Patients who suffer from advanced congestive heart failure and heart rhythm abnormalities may qualify to participate in one of two research trials now underway at ...
Cardiac resynchronization therapy (CRT), with or without a defibrillator, has been shown to improve symptoms, quality of life, and prognosis in patients with moderate-to-severe heart failure (HF) ...
Reduced cardiac efficiency caused by suboptimal synchronization of the heart's normal contraction might contribute to the development of or exacerbate heart failure. Conceptually and in practice ...
With increased recognition of the link between cancer care and heart disease, more studies are evaluating the interconnectedness of cancer survival, chemotherapy, and heart failure (HF) in patients ...
The European Society of Cardiology (ESC) has released updated guidelines for cardiac pacing and cardiac resynchronization therapy (CRT), which emphasize patient-centered care and shared ...
Pacemakers and other implantable devices that restore normal heart rhythms have saved millions of lives. In some patients, a pacemaker or implantable cardioverter defibrillator modified for "cardiac ...
The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Advisory Panel determined that the overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results